

Page 1 of 1

## Assessing a patient for Paxlovid (nirmatrelvir/ritonavir)

Updated 10 March 2022

Please check www.covid19-druginteractions.org for updates.

Data are limited or absent: therefore, risk-benefit assessment for any individual patient rests with prescribers.

Developed by Kirsteen Hill, ID/HIV/COVID Pharmacist, Dundee, Scotland and adapted by Liverpool Drug Interactions Group.

## ANY OF THE FOLLOWING:

- <18 years (check local age restrictions)
- Pregnancy (discuss the benefits/risks of treatment with the patient and a multidisciplinary team)
- Severe renal impairment: eGFR (CrCl if >75years) <30 ml/min
- Severe liver disease: Child Pugh Class C
- Unable to swallow tablets
- Prescribed any medicines below:

Amiodarone Pethidine Alfuzosin\* Phenobarbitone Aliskiren Primidone Pimozide Apixaban\* Bosentan Phenytoin Quetiapine Carbamazepine Ciclosporin Ranolazine Clozapine Rifampicin Rivaroxaban\* Clonazepam Salmeterol\* Colchicine Diazepam\* Sildenafil (pulmonary Disopyramide hypertension) Domperidone\* Simvastatin\* Dronedarone Sirolimus St John's Wort Enzalutamide Eplerenone Tacrolimus Flecainide Tadalafil (pulmonary **Ivabradine** hypertension) Ticagrelor Lercanidipine\* Midazolam (oral) \*unless medicine can be stopped safely for 8 days Note: list of medicines not exhaustive and subject to change



